BRIEF — Fresenius Kabi launches new prefilled syringe

Germany-headquartered health care company Fresenius Kabi has announced the US launch of the Simplist injection of palonosetron hydrochloride.

The latest offering from the company’s Simplist portfolio, it is the first Food and Drug Administration-approved prefilled delivery system for this medication, which is used to prevent acute nausea and vomiting associated with chemotherapy.

John Ducker, president and chief executive of Fresenius Kabi USA, said: “Ready-to-administer delivery systems like this are designed to help improve patient safety and streamline drug preparation. We are pleased to continue to expand our Simplist portfolio to meet the needs of clinicians and the patients they treat.”